

## 06. Implementing new and re-purposed drugs for the treatment of drug-resistant TB: lessons from the field

**THE 46<sup>TH</sup> UNION  
WORLD CONFERENCE  
ON LUNG HEALTH**

CAPE TOWN, SOUTH AFRICA  
2-6 DECEMBER 2015

Thursday, 03 December 2015, 09:00 - 16:00

Room Ballroom West

Type of session	Post-graduate Course
Track	Drug-resistant TB care and treatment, including trials
Track2 (optional)	Patient-centred care
Duration	Full-day
Max attendees	150
Description	There are encouraging data about the successful use of novel and re-purposed medications for the treatment of drug-resistant TB, and the use of such agents is recommended by the World Health Organization. There is, however, limited information about their use in the field. The purpose of this session will be to present information that will assist programmes and providers in the optimal introduction of new and re-purposed TB drugs to ensure the best possible outcomes for patients and programmes. The session will focus on pragmatic issues and provide useful tools for attendees.
Target audience	<ol style="list-style-type: none"> <li>1. Physicians, nurses, community health workers, programme managers</li> <li>2. Other personnel involved in the care of persons with DR-TB</li> <li>3. Funding agencies supporting new drug introduction</li> </ol>
Objectives	<ol style="list-style-type: none"> <li>1. To review data on the use of new drugs under programme conditions</li> <li>2. To discuss optimal use of new drugs, including regimen selection, adverse events and special populations</li> <li>3. To review issues on programme implementation, including pharmacovigilance and operational research</li> <li>4. To discuss legal issues, ethical challenges and patient perspectives</li> <li>5. To provide useful field tools for attendees</li> </ol>
Keywords	New drugs; re-purposed drugs; field tools
Coordinator(s)	Jennifer Furin (USA)
Chair(s)	Erlina Burhan (Indonesia)
Presentations	<ol style="list-style-type: none"> <li>1. New and re-purposed drugs for DR-TB: a brief review of medications and regimens Robert Horsburgh (USA)</li> <li>2. Programmatic introduction of new drugs: WHO framework Christian Lienhardt (Switzerland)</li> <li>3. Regimen selection for new and re-purposed drugs Lorenzo Guglielmetti (France)</li> <li>4. Monitoring and adverse events with a focus on electrocardiograms Francesca Conradie (South Africa)</li> <li>5. New and re-purposed drugs and children Tony Garcia-Pratt (South Africa)</li> <li>6. New and re-purposed drugs and HIV Vivian Cox (South Africa)</li> <li>7. Pharmacovigilance: implementation in the field Sviatlana Setkina (Belarus)</li> <li>8. Ethical issues and informed consent in new drug introduction Liga Kuska (Latvia)</li> <li>9. Activist agenda and new and re-purposed drugs for DR-TB Sharonann Lynch (USA)</li> <li>10. Operational research and new drug implementation Helen Cox (South Africa)</li> </ol>